Literature DB >> 24789683

Decreased expression of NPRL2 in renal cancer cells is associated with unfavourable pathological, proliferation and apoptotic features.

Yongyong Tang1, Li Jiang, Wei Tang.   

Abstract

The tumor suppressor gene nitrogen permease regulator-like 2(NPRL2) NPRL2 expressed obviously in many normal human tissues, but reduced in expression in many human tumors significantly. In this study, we detected the expression of NPRL2 in 78 clear cell renal cell carcinoma (ccRCC) by immunohistochemistry and correlated it with clinicopathological parameters. Meanwhile, the function of NPRL2 in human ccRCC was further explored after transfected recombinant expressing plasmids pEGFP-N1-NPRL2 into human renal cancer 786-0 cells. NPRL2 protein showed high expression in 67 of 78 cases of adjacent normal tissues (85.9 %), which was significantly higher than that in ccRCC tissues (23/78, 29.5 %). Clinic pathological analysis showed that NPRL2 expression was significantly correlated with histological grade (P = 0.044), TNM stage (P = 0.025) and lymph node metastasis (P = 0.028). MTT assay demonstrated that NPRL2 could obviously inhibit renal cancer cell proliferation. Flow cytometric analysis revealed that NPRL2 could induce renal cancer cells apoptosis and arrest the cell cycle in G0/G1 phase. In conclusion, NPRL2 is closely correlated to unfavourable pathological, proliferation and apoptotic features in ccRCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24789683     DOI: 10.1007/s12253-014-9761-2

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  27 in total

1.  Expression of candidate chromosome 3p21.3 tumor suppressor genes and down-regulation of BLU in some esophageal squamous cell carcinomas.

Authors:  Paulisally Hau Yi Lo; Alfred Chi Chung Leung; Wenjun Xiong; Simon Law; Fuh-Mei Duh; Michael I Lerman; Eric J Stanbridge; Maria Li Lung
Journal:  Cancer Lett       Date:  2006-03-28       Impact factor: 8.679

Review 2.  Matrix metalloproteinases.

Authors:  S L Parsons; S A Watson; P D Brown; H M Collins; R J Steele
Journal:  Br J Surg       Date:  1997-02       Impact factor: 6.939

3.  Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma.

Authors:  Eiji Hirota; Liang Yan; Tatsuhiko Tsunoda; Shingo Ashida; Makoto Fujime; Taro Shuin; Tsuneharu Miki; Yusuke Nakamura; Toyomasa Katagiri
Journal:  Int J Oncol       Date:  2006-10       Impact factor: 5.650

4.  NPRL2 gene expression in the progression of colon tumors.

Authors:  B Yogurtcu; I Hatemi; I Aydin; N Buyru
Journal:  Genet Mol Res       Date:  2012-09-12

5.  Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer risk.

Authors:  Jin Hee Kim; Heon Kim; Kye Young Lee; Kang-Hyeon Choe; Jeong-Seon Ryu; Ho Il Yoon; Sook Whan Sung; Keun-Young Yoo; Yun-Chul Hong
Journal:  Hum Mol Genet       Date:  2006-02-23       Impact factor: 6.150

6.  TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling.

Authors:  Atsuo Kurata; Ryohei Katayama; Toshiki Watanabe; Takashi Tsuruo; Naoya Fujita
Journal:  Cancer Sci       Date:  2008-07-04       Impact factor: 6.716

7.  RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma.

Authors:  Lillian Shuk-Nga Chow; Kwok-Wai Lo; Joseph Kwong; Ka-Fai To; Kam-Sze Tsang; Ching-Wan Lam; Reinhard Dammann; Dolly P Huang
Journal:  Int J Cancer       Date:  2004-05-10       Impact factor: 7.396

8.  Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma.

Authors:  Yi-Jun Xue; Ri-Hai Xiao; Da-Zhi Long; Xiao-Feng Zou; Xiao-Ning Wang; Guo-Xi Zhang; Yuan-Hu Yuan; Geng-Qing Wu; Jun Yang; Yu-Ting Wu; Hui Xu; Fo-Lin Liu; Min Liu
Journal:  J Transl Med       Date:  2012-09-24       Impact factor: 5.531

9.  HYAL1 and HYAL2 inhibit tumour growth in vivo but not in vitro.

Authors:  Fuli Wang; Elvira V Grigorieva; Jingfeng Li; Vera N Senchenko; Tatiana V Pavlova; Ekaterina A Anedchenko; Anna V Kudryavtseva; Alexander Tsimanis; Debora Angeloni; Michael I Lerman; Vladimir I Kashuba; George Klein; Eugene R Zabarovsky
Journal:  PLoS One       Date:  2008-08-22       Impact factor: 3.240

View more
  5 in total

Review 1.  SEA you later alli-GATOR--a dynamic regulator of the TORC1 stress response pathway.

Authors:  Svetlana Dokudovskaya; Michael P Rout
Journal:  J Cell Sci       Date:  2015-05-01       Impact factor: 5.285

2.  Nitrogen Permease Regulator-Like-2 Exhibited Anti-Tumor Effects And Enhanced The Sensitivity Of Colorectal Cancer Cells To Oxaliplatin And 5-Fluorouracil.

Authors:  Aiyun Liu; Jiutao Qiao; Liyuan He; Zhangmeng Liu; Jing Chen; Fenghua Pei; Yaju Du
Journal:  Onco Targets Ther       Date:  2019-10-18       Impact factor: 4.147

Review 3.  SEA and GATOR 10 Years Later.

Authors:  Yahir A Loissell-Baltazar; Svetlana Dokudovskaya
Journal:  Cells       Date:  2021-10-08       Impact factor: 6.600

4.  Bioinformatics analysis of the prognostic and immunotherapeutic significance of NPRL2 in stomach adenocarcinoma.

Authors:  Yilin Pi; Yuning Zhan; Jitao Song; Xin Jin; Jing Chen
Journal:  J Gastrointest Oncol       Date:  2022-08

Review 5.  Conserved regulators of Rag GTPases orchestrate amino acid-dependent TORC1 signaling.

Authors:  Katie Powis; Claudio De Virgilio
Journal:  Cell Discov       Date:  2016-03-08       Impact factor: 10.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.